OLX-07010 is an oral small molecule inhibitor of tau self-association which is poised to enter first in human dosing soon. Because OLX-07010 has demonstrated activity in animal models representing tau aggregation in Alzheimer’s disease and rare tauopathies, Oligomerix is pursuing both indications for clinical development.
